retatrutide triple agonist glp-1 gip glucagon phase 2 obesity Retatrutide is not “just another GLP1.” It is a triple agonist: GLP-1 + GIP + glucagon. Translation: it targets appetite, insulin biology, energy expenditure, weight, glucose control, liver fat and broader metabolic

FDA is moving to restrict mass marketed compounded GLP 1 products that aren't FDA approved, warning companies they can't market them as equivalent to approved drugs and signaling stronger enforcement to protect patients from unverified GLP1 Injections and Pregnancy: What You Need to Know What should you do when a patient doesn't respond to a GLP 1? You've titrated the dose. You've optimized lifestyle support. They're adherent, motivatedand still, there is no expected weight loss. Before assuming As a doctor, I'm seeing more and more research around GLP 1 medications and brain health These meds aren't just for weight loss anymore they may help reduce inflammation, improve insulin sensitivity Muscle Mass and Glucagon Like Peptide 1 Receptor Agonists: Adaptive or Maladaptive Response to Weight Loss? Circulation